| 摘要 |
The compounds of the general Formula (I) are useful as inhibitors of blood coagulation in an ex-vivo situation such as, for example, the storage of whole blood or other biological samples suspected to contain Factor Xa and in which coagulation is detrimental. Wherein; A is a 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring heteroatoms selected from nitrogen; B is an optionally substituted phenylene ring; T1 is CH or N; T2 is CH or N; with the proviso that at least one of T1 and T2 is N; X1 is SO, SO2, C(R4)2 or CO when T1 is CH or N; or in addition X1 is O or S when T1 is CH; and wherein each R4 is independently hydrogen or C1-4alkyl; L 1 is C1-4alkylene or C1-3alkylenecarbonyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; or R2 and R3 are joined to form a C1-4alkylene or -CH2CO- group; with the proviso that when T1 and T2 are both N, L1 is not methylene and R2 and R3 together are not methylene; X2 is S(O)y wherein y is one or two, C(R5)2 or CO; and each R5 is hydrogen or C1-4alkyl; Q is phenyl, naphthyl, phenylC1-4alkyl, phenylC2-4alkenyl. phenylC2-4alkynyl or a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur and Q is optionally substituted; and pharmaceutically acceptable salts thereof. Further structures illustrated as Formula (II), (III) and (IV) are examples of the disclosed application.
|
